- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to incorporation by reference of our report dated April 16, 2024, with respect to the consolidated balance sheets of AXIM Biotechnologies, Inc. as of December 31, 2023 and 2022 and the related consolidated statement of operations, statement of shareholders’ deficit and cash flows for each of the years in the two-year period ended December 31, 2023, which includes an explanatory paragraph regarding the substantial doubt about the Company’s ability to continue as a going concern, included in this Annual Report on Form 10-K of Axim Biotechnologies, Inc. (the ”Company”). We hereby consent to the incorporation by reference of said report in the Registration Statements of Axim Biotechnologies, Inc. on Form S-1 (File No. 333-272390); Form S-8 (File No. 333-265580) and Form S-8 (File No. 333-204574).
/s/ RBSM LLP
RBSM LLP
New York, New York
April 16, 2024